Eli Lilly and Company (LLY) stands as a stalwart in the pharmaceutical sector, characterized by its remarkable dividend consistency with a 55-year history of uninterrupted payouts. Despite a modest dividend yield of 0.60%, the company shows robust earnings and free cash flow payout ratios, indicating a healthy dividend coverage. Furthermore, the company demonstrates a commendable, stable dividend growth rate which signifies potential for future income appreciation. These factors combined position LLY as an attractive consideration for dividend-oriented investors seeking reliability.
The overview of Eli Lilly and Company's dividend profile underscores its robust and sustained commitment to dividend payout, characteristic of its sectoral prominence in pharmaceuticals.
| Metric | Value |
|---|---|
| Sector | Pharmaceuticals |
| Dividend yield | 0.60% |
| Current dividend per share | $5.9955 |
| Dividend history | 55 years |
| Last cut or suspension | None |
LLY's dividend history exhibits consistency with regular annual increases. This track record showcases the management's commitment to return capital to shareholders, which is paramount for long-term income investors.
| Year | Dividend Per Share (USD) |
|---|---|
| 2026 | $1.73 |
| 2025 | $6.00 |
| 2024 | $5.20 |
| 2023 | $4.52 |
| 2022 | $3.92 |
Divident growth is an essential indicator of financial health and LLY demonstrates a steady growth rate over the years. This stability is crucial for attracting long-term investors.
| Time | Growth |
|---|---|
| 3 years | 15.24% |
| 5 years | 15.18% |
The average dividend growth is 15.18% over 5 years. This shows moderate but steady dividend growth.
The payout ratio is a critical assessment tool to determine the sustainability of a company's dividend policy. LLY's coverage ratios indicate a conservative payout strategy.
| Key Figure | Ratio |
|---|---|
| EPS-based | 26.09% |
| Free cash flow-based | 63.14% |
With a low EPS payout ratio of 26.09% and a modest FCF payout ratio of 63.14%, LLY maintains a sustainable dividend policy, signaling financial prudence.
Evaluating cash flow and capital efficiency provides insights into the liquidity and capital allocation strategies of LLY, underpinning its dividend distributability.
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Free Cash Flow Yield | 0.93% | 0.06% | -0.60% |
| Earnings Yield | 2.14% | 1.52% | 1.00% |
| CAPEX to Operating Cash Flow | 46.64% | 95.30% | 174.34% |
| Stock-based Compensation to Revenue | 0.96% | 1.43% | 1.84% |
| Free Cash Flow / Operating Cash Flow Ratio | 53.36% | 4.70% | -74.34% |
The fluctuating metrics in recent years point towards variable cash flow stability, influencing the company's potential to finance dividends and other capital expenditures.
Analyzing leverage and ratios provides a picture of LLY's financial resilience and its ability to meet long-term obligations.
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Debt-to-Equity | 160.18% | 237.06% | 234.18% |
| Debt-to-Assets | 37.79% | 42.74% | 39.41% |
| Debt-to-Capital | 61.56% | 70.33% | 70.08% |
| Net Debt to EBITDA | 1.27 | 1.99 | 2.62 |
| Current Ratio | 1.58 | -- | -- |
| Quick Ratio | 1.19 | 0.89 | 0.73 |
| Financial Leverage | 4.24 | 5.55 | 5.94 |
This analysis indicates a stable debt profile with a slight increase in leverage, requiring ongoing monitoring to maintain balance sheet health.
Understanding the fundamental and profitability metrics of LLY offers insights into operational efficiency and competitive positioning.
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Return on Equity | 77.78% | 74.62% | 48.65% |
| Return on Assets | 18.35% | 13.45% | 8.19% |
| Net Margin | 31.66% | 23.51% | 15.36% |
| EBIT Margin | 40.46% | 29.88% | 20.63% |
| EBITDA Margin | 42.86% | 33.81% | 25.11% |
| Gross Margin | 83.79% | 81.31% | 79.25% |
| Research & Development to Revenue | 20.46% | 24.40% | 27.29% |
High returns on equity and assets illustrate LLY's proficiency in utilizing its resources to generate profits, solidifying its market position.
| Criterion | Score | |
|---|---|---|
| Dividend yield | 3 | |
| Dividend Stability | 5 | |
| Dividend Growth | 4 | |
| Payout Ratio | 4 | |
| Financial Stability | 4 | |
| Dividend Continuity | 5 | |
| Cashflow Coverage | 3 | |
| Balance Sheet Quality | 4 |
Eli Lilly and Company emerges as a compelling dividend investment for those valuing safety and consistency. With its long-standing history of dividends, a prudent payout ratio, and consistent financial performance, LLY is recommended for income-focused portfolios seeking steady growth. However, investors should remain mindful of its comparatively low yield relative to industry peers.
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.